A 15-mer phosphorothioate antisense oligonuclide (ASON) complementary to the translation start region of the C-myc oncogene mRNA was radioiodinated to enhance its antitumor activity, and vasoactive intestinal peptide bound covalently polylysine (VIPpolylysine) was used as a carrier to deliver the oligonucleotide into VIP receptor-positive tumor cells. 
T he use of antisense oligonucleotide(ASON) as a therapeutic agent for cancer has been proposed for more than 10 years. Phosphorothioate ASONs have been successfully used in a large number of experiments designed to downregulate gene expression and used in several clinical therapeutic trials. The preclinical development of several ASONs targeting cancer-relevant genes has been proceeding very rapidly. [1] [2] [3] Antisense targeting the human C-myc oncogene has shown convincing reduction in target gene expression and promising activity against a variety of human malignancies in vitro and in vivo. [4] [5] [6] However, despite that ongoing clinical trials have shown some encouraging preliminary results, the use of ASON for inhibition of oncogene expression raises several problems, including difficulty of ASON to cross cell membrane and nonselectivity of cells in the uptake of ASON. In fact, considering the multigenic defects of human tumors, inhibition of a single target gene is not sufficient to suppress tumor growth. 7 The combination of ASON targeting to specific genes involved in tumor progression with radionuclides emitting a or b particle represents an attractive strategy for improving cancer treatment. The effects of radioactive-labeled oligodeoxynucleotides may be both direct antisense inhibition and radiation damage.
The efficacy of antisense therapy depends on efficient delivery of oligonucleotides into target cells. In order to increase their therapeutic efficacy, several approaches have been explored to enhance permeability and cellular uptake of ASON, including conjugation to polycation, 8, 9 linking to carrier peptides, 10, 11 coupling to cholesterol, 12 encapsulation into lipid particles such as microspheres and liposomes. [13] [14] [15] The use of vectors in antisense delivery in vivo seems to improve their biological effects. To date, asialoglycoprotein, transferrin, folate and several other ligands have been studied as carriers to deliver ASON by their receptors mediated endocytosis. [16] [17] [18] [19] [20] It has shown that most primary human tumors, including human colon cancer, express VIP receptors at high incidence and high density, and ligands are internalized by cells possessing VIP receptor subsequent to endocytosis. 21, 22 Thereby, the use of VIP as a vector for carrying radiolabeled ASON into a specific location inside a tumor cell contributes an attractive delivery system.
We have previously demonstrated that phosphorothioate ASON complementary to the translation start region of the C-myc oncogene mRNA can specifically accumulated in HT29 colon tumor cells by conjugation with VIP. 23 In this approach, the radiolabeled ASON was conjugated covalently with polysine to neutralize the negative charge and linked to VIP for specific delivery to colon tumor cells. In the present study, we investigate further the tumor targeting potential and antitumor effect in vivo of VIP-131 I-ASON in HT29 human colon adenocarcinoma xenografts.
Materials and methods

Materials
The 15-mer phosphorothioate ASON(5'-AACGTT-GAGGGGCAT-3'), which is complementary to the translation start region of the C-myc oncogene mRNA, was purchased from GiBcoBRL(USA). The scrambled oligonucleotide (5'-CTAGGAATGCAGTGG-3') was used as control. All oligodeoxynucleotides used in these studies were purchased from the same source as the uniform phosphorothioates. Human colon carcinoma HT29 cell line was obtained from internal laboratory of our hospital (West China hospital) and the cells were grown in RPM1640 medium(Introgene) containing penicillin at 100 U/ml, streptomycin at 100 U/ml, and supplemented with 10% fetal calf serum. The cells were maintained as monolayer in a humidified 5% carbon dioxide atmosphere.
Preparation of antisense radiopharmaceutical
The oligonucleotides were labeled with 125 I or 131 I according to a previous method. 24 . The radioiodinated oligodeoxynucleotides mixtures were chromatographed on Sephdex G-25(Sigma), eluting with ammonium acetate buffer (0.1 mol/l, pH ¼ 5). The radiochemical purity of radioiodinated ASON was 497% as determined by thin layer chromatogram (TLC).
Poly(L-lysine) (Sigma), molecular weight 3000, was coupled to VIP in a 1:1 molar ratio by using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC; Sigma) at pH 7.3 as described previously. 23 The reaction mixture was fractionated by gel filtration on a Superose 6 column with the FPLC system (Pharmacia). Once the conjugate was made and purified, fractions from the FPLC were analyzed by SDS/PAGE to determine which fraction contained only modified VIP(VIP-polylysine conjugate). These fractions were then pooled and dialyzed against HBS (150 mmol/l NaCl/20 mmol/l Hepes, pH 7.3). VIPradioiodinated ASON complexes were prepared by adding radioiodinated ASON directly to VIP-polylysine solution in a molecular ratio of 1:2 while mixing. The mixture was incubated at room temperature for 30 minutes. Immediately after the incubation, the complex was analyzed on 2% agarose gels and electrophoresed in 1 Â TAE(40 mmol Tris acetate/1 mmol EDTA, pH 8) running buffer.
Receptor binding
For receptor binding studies, human colon carcinoma HT29 cells in 24-well plates were washed 3 times with RPM1640 medium. Then 250 ml of receptor binding medium (RPM1640 containing 2% BSA and 2 mg/ml bacitracin) and 100,000 cpm 125 I-VIP (VIP was radioiodinated using the chloramine T procedure) were added in the absence or the presence of VIP-ASON (competitor). After incubation at 371C for 30 minutes, the plates were rinsed 3 times with receptor binding medium. The cells containing bound peptide were dissolved in 0.2 mol/l NaOH and counted in a gamma counter.
Colon cancer xenograft
Four-to 6-week-old athymic male BALB/c mice(body weight, 20-25 g) were injected subcutaneously with 1.0 Â 10 7. HT29 cells in the right upper flank. After 5-7 days, mice bearing tumor of 15-115 mm 3 were selected for the experiments.
In vivo pharmacokinetics of the VIP-125 I-ASON Adult male BALB/c mice were divided into five groups of three mice each for the pharmacokinetic study. The 100 ml injection solution contained 185 kBq of 125 I-ASON with or without conjugation to VIP-polylysine was administered through the lateral tail vein of each mouse. The mice of five groups were killed at 0.5, 2, 5, 15, and 60 minutes after injection and arterial blood was sampled from the aorta. After spinning the blood samples, the collected supernatant was counted for 125 I radioactivity using a g-counter. An aliquot of serum was precipitated with cold 10% TCA, and the fraction of total serum radioactivity that was TCA precipitated was determined. Pharmacokinetic parameters were calculated by fitting the serum TCA-precipitable radioactivity data to a biexponential equation with a weighting factor of [1/ A(t)] 2 using a derivative-free nonline regression analysis:
Àk2t , where A(t) ¼ %injected dose (%ID)/ml serum at a given time (t).
Organ and tumor uptake of the VIP- Normal tissue toxicity was evaluated by measuring body weight every 3 days and obtaining peripheral blood cell counts, plasma ALT, and CR levels at the end of 4-week observation period. A body weight index was calculated by dividing the body weight at each time point by the initial body weight.
Statistical analysis
All statistical analyses were carried out with the SPSS software 10.0. Student's t-test, one-way analysis of variance and w 2 tests were used according to the data obtained and Po.05 was considered statistically significant.
Results
Formation of VIP-
I-ASON complexes
The 125 I-ASON binding to the VIP-polylysine was demonstrated by mobility shift in an 2% agarose gel with 1 Â TAE (40 mmol Tris acetate/1 mmol EDTA, pH 8) running buffer (Fig 1) . Judged on the basis of charge neutralization, interaction between the ASON and VIPpolylysine conjugate was observed by the reduction of electrophoretic mobility of the ASON. The ASON migration was completely retarded when ASON and VIP-polylysine molar ratio was 1:2.
VIP-ASON bind to colon cancer cells with high affinity
The specificity of VIP-ASON binding to HT29 colon cancer cells was investigated by competing against 125 I-VIP (Fig 2) . VIP-ASON had little effect of 125 I-VIP binding at 10 À11 mol/l whereas almost all specific binding was inhibited at 10 À6 mol/l. VIP-ASON inhibited specific binding of 125 I-VIP to HT29 colon cancer cells in a dosedependent manner with IC50 value of 6.1 Â 10 À8 mol/l. The result indicate that VIP-ASON can be recognized by VIP receptor on HT29 colon cancer cells, although with somewhat reduced affinity as compared with unmodified VIP. 22 In vivo pharmacokinetics of the VIP-125 I-ASON
The pharmacokinetic parameters are shown in Table 1 .
The unconjugated ASON had a rapid distribution phase (T 1/2a 2.018 minutes) followed by a prolonged elimination phase (T 1/2b 83.375 minutes). The conjugation of the ASON to VIP-polylysine resulted in a 5.6-fold decrease in the plasma clearance (CL) (Po.001) and a nearly six-fold increase in the area under the plasma concentration-time curve (AUC) (P ¼ .001).
The metabolic stability of the radioiodinated ASON was enhanced after conjugation to the VIP-polylysine based on measurements of serum radioactivity that was precipitated by TCA. For the unconjugated 125 I-ASON, the serum TCA precipitation was 88%71, 82%73, and 6672% at 5, 15, and 60 minutes after injection, respectively. For the VIP-125 I-ASON, the serum TCA precipitation was 9572, 9373, 8673 and 8272% at 5, 15, 60, and 120 minutes after injection, respectively. Table 2 ). The in vitro quantification of radioactivity revealed that uptake of the 125 I-ASON by VIP receptor-rich organs such as lung and liver was increased by conjugation to the VIP. At 24 h after injection, accumulation of VIP-125 I-ASON in the tumors was significantly higher than that of 125 I-ASON (P ¼ .01). Furthermore, it is worth noting that tumor-to-muscle ratios reached 8.13 for VIP-125 I-ASON and 3.6 for 125 I-ASON at 24 hours postinjection. As we know, a particularly high ''tumor to background'' ratio (where background represents nontumor tissue) is preferable for radiotherapeutic as well as diagnostic application.
Treatment of mice bearing HT29 human colon tumor xenogram
The tumor growth index-versus-time curves of mice treated with 4 weekly doses of VIP-131 I-ASON or control pharmaceuticals are shown in Figure 3 . The slopes of the tumor growth curves are summarized in Table 3 . No significant antitumor effects were observed in mice treated with 131 I-ASON or VIP-131 I-MON compared with salinetreated control mice (P ¼ .997 and 1.000). VIP-ASON appeared to inhibit the growth of HT29 tumor xenografts, but the effects were significantly lower than that of VIP-131 I-ASON (P ¼ .002), and the difference in the slopes of the tumor growth curves for VIP-ASON-treated and normal saline-treated mice did not quite reach statistical significance (P ¼ .150). On the contrary, VIP-131 I-ASON exhibited strong antitumor effects against HT29 xenografts, decreasing tumor growth rate 9.67-, 7.90-fold more effectively than 131 I-ASON and VIP-ASON, respectively, at equivalent doses (Fig 3a) .
Tumor growth inhibition by VIP-131 I-ASON was dosedependent (Fig 3b) . The tumor growth indices at 9 day after the start of treatment for mice administered totals of 3.7, 7.4, and 18. (Fig 4) . There was a decrease in leukocyte (WBC) and platelet counts in mice treated with VIP-131 I-ASON compared with normal saline-treated mice (Table 4) , but these counts remained in the normal ranges. 25 
Discussion
One obstacle to widespread use of ASON is apparent nonselectivity of cells of different lineages and of different growth states in the uptake of oligodeoxynucleotides. This lack of selectivity in oligodeoxynucleotides uptake could be a major obstacle in developing an antisense therapy, since the targeted oncogene-encoded mRNA is often identical in normal and tumor cells. As a step toward enhancing the targeting selectivity and thereby the antitumor effect of these reagents on tumor cells, we exploited the abundant expression of VIP receptor on the HT29 cell surface to deliver a C-myc ASON linked to a VIP conjugate. The interaction of this conjugate with the VIP receptor was demonstrated by its ability to compete with 125 I-VIP for binding to the VIP receptor. Moody et al have coupled ellipticine to VIP by tera-or pentapeptide and investigated the effects of the derivatives on VIPexpressed breast cancer cells. 22 Their results were in agreement with those reported here. The VIP-ellipticine conjugate competed against 125 I-VIP binding to breast cancer cells and inhibited the clonal growth of breast cancer cells. These data demonstrated the possibility of using VIP as a carrier for antitumor drug delivery. In the present investigation, VIP-131 I-ASON showed 9.67-fold more antitumor effects than 131 I-ASON, and the improved antitumor efficacy in consistent with the increased tumor uptake -the conjugation of the ASON to the VIP contribute to the over three-fold increase in tumor uptake of radioiodinated ASON. It was more remarkable that the tumor-to-muscle ratio for VIP-125 I-ASON was profoundly higher than for 125 I-ASON, suggesting that the radioiodinated ASON conjugated to VIP could accumulated in tumor in vivo via VIP receptor mediated endocytosis.
The increased tumor accumulation of VIP-125 I-ASON is concordant with the high VIP receptor density on HT29 colon cancer cells, but the improved pharmacokinetic behavior may be another explanation of increased tumor accumulation. In pharmacokinetics studies, VIP-131 I-ASON conjugate showed a 5.9-fold increase in the AUC compared with unconjugated 131 I-ASON. The conjugation of the 4800 Da ASON to the 10,000 Da VIP-polysine targeting system results in a greatly increase in molecular size. This increase in size decreases systemic clearance, which may be due to blocking of glomerular filtration and renal clearance of the ASON. It had been previously reported that the large size of peptide polyplex conjugate eliminated glomerular filtration of oligonucleotides and Antitumor effects of VIP-131 I-ASON X Ou et al increased the AUC. 26 Conjugation of the ASON to the targeting vector redirected the antisense agent from kidney to VIP receptor-rich organs such as lung and liver, whereas higher hepatic uptake could be partially due to a molecular size difference. Localization of the radioactivity in lung and liver may limit the activity dose that can be administered safely.
The other associated problem of antisense therapy concerns the difficulty in introducing oligonucleotide into target cells at concentration sufficient to bind to the complementary mRNA. The inefficient intracellular localization of antisense DNAs explains, in part, the large dosages (e.g., 2 mg/kg/day over 20 day) now being administered to the patients in connection with antisense chemotherapy. 27, 28 Administration of gram quantities of ASON may increase drug costs and toxicities. 29, 30 Several evidences from cell cultures have established that the combination of antisense targeting genes involved in cell proliferation and apoptosis with radionuclides radiation is a promising approach for cancer therapy. It has proved that radiolabeled antisense oligonucleotides can not only hybridize to target RNA but also accumulate in tumor cell by an antisense mechanism. 31, 32 Furthermore, Kairemo et al 33 have shown that oligonucleotide therapy can be effective with the phosphorothioates ASON internally labeled with 32P, 33P, and 35S. Studies also performed to select the radionuclides and the cell nuclear absorbed doses of radiolabeled oligonucleotides were estimated in different cellular dimensions. [34] [35] [36] In present study, ASON was radiolabeled with 131 I because of its appropriate range of the b-emissions, its availability and ease of labeling, and the therapeutic potential of the VIP-131 I-ASON was assessed. The treatment study demonstrates that VIP-131 I-ASON has potent, dose related, and selective tumor growthinhibitory effects on human colon tumor xenograft. Our findings are consistent with the following conclusions. Preclinical toxicology studies have demonstrated that the ASON has dose-and infusion rate-dependent side effects such as hypotension and anticoagulant effect. 37 In present study, no significant antitumor effects was observed in mice treated with VIP-ASON at the very low dose (total, 100 mg/mouse) used in this study. In comparison, an equivalent oligonucleotide dose of VIP-131 I-ASON exhibited strong antitumor effects against HT29 xenografts. The reducing dose of ASON may represent an important clinical advance toward increasing the oligonucleotide radiotherapy. Finally, the tumor inhibitory may be attributed to, at least in part, tumor accumulation of ASON by an antisense mechanism, Since significantly stronger antitumor effects of VIP-131 I-ASON was observed than radiolabeled random control DNAs conjugated to VIP.
In general, the dose-limiting toxicities for the radionuclide therapy are hematologic and gastrointestinal. No changes in hemoglobin and erythrocyte counts in mice administered VIP-131 I-ASON were observed in present study, but there were moderate (1.4-to 1.6-fold) decreases in WBC and platelet counts compared with those in normal saline-treated control mice. Nevertheless, the WBS and platelet counts remained in the normal ranges. Because very few of the bone marrow stem cell population expresses VIP receptor, hematopoietic toxicity is not anticipated in this study. We hypothesize that the decreases in WBC and platelet counts may be attributable to nonspecific radiotoxicity to bone marrow stem cells caused by the cross-fire irradiation of b-emissions and penetrating g-emissions by 131 I. There were no significant changes in body weight over 4 week in mice administered a total of 92.5 MBq of VIP-131 I-ASON. Despite high level of radioactivity accumulation in the liver and kidney, there was just slight increase in the plasma ALT and no significant increase in the CR levels, indicating no major toxicity to the liver or kidney. The well tolerance of normal tissue was likely attributable to the higher accumulation of the VIP-131 I-ASON in tumor xenografts. As a significant proportion of the radioiodinated ASON was in the tumor, there was less present in the circulation and also reduced cross-fire irradiation of distant normal tissues by the short-range b-emissions of 131 I.
Conclusion
These studies provide support for the hypothesis that it is possible to inhibit growth of human colon cancer in vivo by ASON labeled with b-emissions radionuclide and conjugated to VIP-polylysine. The radiopharmaceutical was well tolerated, demonstrating minimal normal tissue toxicity and causing modest decrease in WBC and platelet counts. No hepatotoxicity or renal toxicity was associated with VIP-131 I-ASON. These findings might afford a new idea or method for the therapy of colon cancer. The further studies of cell level and animal model are necessary to examine whether there is chronic toxicity when being used for a long time in vivo. Optimization of this therapy by modifying the structure of ASON and the choice of radionuclide could further improve the therapeutic potential.
